Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | FBRX |
---|---|---|
09:32 ET | 2832 | 0.49 |
09:36 ET | 200 | 0.48 |
09:38 ET | 7688 | 0.489 |
09:39 ET | 10433 | 0.4501 |
10:24 ET | 100 | 0.4923 |
10:30 ET | 4100 | 0.5029 |
10:33 ET | 983 | 0.4921 |
10:39 ET | 500 | 0.504771 |
11:29 ET | 200 | 0.4999 |
11:33 ET | 113 | 0.4978 |
12:41 ET | 200 | 0.4995 |
12:43 ET | 500 | 0.492 |
12:57 ET | 100 | 0.492 |
01:10 ET | 4700 | 0.5197 |
01:39 ET | 700 | 0.505 |
01:44 ET | 125 | 0.5 |
01:57 ET | 5446 | 0.478 |
02:00 ET | 4093 | 0.46 |
02:15 ET | 6033 | 0.509899 |
02:24 ET | 200 | 0.4938 |
02:26 ET | 100 | 0.478 |
02:27 ET | 100 | 0.478 |
02:29 ET | 200 | 0.478 |
02:38 ET | 100 | 0.478 |
02:49 ET | 100 | 0.4775 |
03:00 ET | 1201 | 0.51 |
03:09 ET | 100 | 0.478 |
03:20 ET | 200 | 0.478 |
03:27 ET | 100 | 0.478 |
03:41 ET | 100 | 0.4777 |
03:45 ET | 100 | 0.4775 |
03:50 ET | 200 | 0.475 |
03:52 ET | 100 | 0.51 |
03:56 ET | 300 | 0.463 |
03:57 ET | 200 | 0.4625 |
03:59 ET | 100 | 0.46 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Forte Biosciences Inc | 16.8M | -0.4x | --- |
Vincerx Pharma Inc | 16.9M | -0.3x | --- |
Kintara Therapeutics Inc | 16.5M | -0.1x | --- |
Microbot Medical Inc | 16.4M | -1.2x | --- |
CytoMed Therapeutics Ltd | 23.5M | -7.0x | --- |
Bioxytran Inc | 16.0M | -3.1x | --- |
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Company’s FB-102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets. It owns one United States patent for administering a combination of Gram-positive and Gram-negative bacteria along with metabolites for treatment of a wide variety of skin conditions. The Company’s subsidiaries include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $16.8M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 36.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.06 |
EPS | $-1.03 |
Book Value | $0.97 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.